warfarin and Ulcer

warfarin has been researched along with Ulcer* in 7 studies

Reviews

1 review(s) available for warfarin and Ulcer

ArticleYear
Review article: gastrointestinal bleeding with low-dose aspirin - what's the risk?
    Alimentary pharmacology & therapeutics, 2006, Sep-15, Volume: 24, Issue:6

    This review examines ulcers and gastrointestinal bleeding with low-dose aspirin, focusing on randomized placebo-controlled trials. The single endoscopic trial assessing ulcers showed no significant difference in 12-week ulcer incidence: 6% of 381 given placebo vs. 7% of 387 given 81 mg enteric-coated aspirin. The relative risk of major gastrointestinal bleeding with low-dose aspirin in a meta-analysis of placebo-controlled trials of vascular protection was 2.07 (95% CI: 1.61-2.66). The absolute rate increase with aspirin above placebo was 0.12% per year (95% CI: 0.07-0.19%) with a number-needed-to-harm of 833 patients (95% CI: 526-1429). A meta-analysis of aspirin 50-1500 mg daily reported an odds ratio for any gastrointestinal bleeding of 1.68 (95% CI: 1.51-1.88) with an number-needed-to-harm at 1 year of 247. The relative risk of hospitalization for upper gastrointestinal bleeding with low-dose aspirin in a large Danish cohort study was 2.6 (95% CI: 2.2-2.9) with an absolute annual incidence of 0.6%. Factors that may increase the risk of gastrointestinal bleeding include prior history of ulcers or gastrointestinal bleeding, corticosteroid use, anticoagulant therapy and addition of a non-aspirin non-steroidal anti-inflammatory drug. When determining whether low-dose aspirin is appropriate for an individual patient, the cardiovascular benefit must be weighed against the potential for clinical events such as gastrointestinal bleeding.

    Topics: Adrenal Cortex Hormones; Aging; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Drug Administration Schedule; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Humans; Randomized Controlled Trials as Topic; Risk Factors; Ulcer; Warfarin

2006

Other Studies

6 other study(ies) available for warfarin and Ulcer

ArticleYear
Outcomes of Anticoagulant Therapy with Low-Molecular-Weight Heparin (LMWH) and Warfarin for Thromboangiitis Obliterans (TAO).
    Current vascular pharmacology, 2021, Volume: 19, Issue:6

    Thromboangiitis obliterans (TAO) is a chronic, non-atherosclerotic, progressive inflammatory vascular disease affecting the small- and medium-size arteries and veins of the extremities.. To evaluate whether long-term anticoagulation with low-molecular-weight heparin (LMWH) and warfarin is beneficial for treating the inflammation and symptoms associated with TAO.. Patients with TAO who underwent anticoagulation as the mainstay of treatment were included in this prospective study. Rest pain relief and healing of trophic lesions (as the primary and secondary endpoint) were investigated at Day 14 and after 6 months of follow-up. High sensitivity C-reactive protein (hsCRP), monocyte count, and ankle-brachial index (ABI) were recorded, and the difference was compared before and after 2-week anticoagulation. The Chi-square test was used to compare the difference between anticoagulant and aspirin groups (based on the literature).. From 2014 to 2019, 18 patients were included. Only 1 patient with wet gangrene received endo-therapy for a failing stent at the start of treatment. After ~14 days, 12 of 13 (92%) patients showed complete ulcer healing, and 17 of 18 (94%) patients showed complete relief from rest pain. Monocyte-counts and hsCRP levels decreased significantly (p<0.001) after a 2-week period of anticoagulation with LMWH. The mean follow-up was 2.6 years (range 0.5-5 years). At 6 months, all patients showed relief of rest pain and complete healing of trophic lesions. All endpoints were significantly improved compared with the aspirin group (p<0.01), and no rest pain or ulcer/gangrene recurred during follow-up.. Anticoagulant therapy may alleviate the inflammation and symptoms of TAO.

    Topics: Anticoagulants; Aspirin; C-Reactive Protein; Gangrene; Heparin, Low-Molecular-Weight; Humans; Inflammation; Pain; Prospective Studies; Thromboangiitis Obliterans; Treatment Outcome; Ulcer; Warfarin

2021
Pradaxa-induced esophageal ulcer.
    BMJ case reports, 2015, Oct-09, Volume: 2015

    Pradaxa (dabigatran) is a direct thrombin inhibitor approved for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. We describe a case of esophageal ulceration associated with Pradaxa administration in a 75-year-old man. The patient reported difficulty swallowing and a burning sensation after taking his first dose of Pradaxa. An esophagogastroduodenoscopy (EGD) revealed linear ulcerations in the mid-esophagus. Pradaxa was held beginning the day before the EGD. The patient reported that his pain and difficulty swallowing resolved on stopping Pradaxa. Pradaxa is formulated with a tartaric acid excipient to reduce variability in absorption. We hypothesise that the capsule lodged in the patient's esophagus and the tartaric acid may have caused local damage resulting in an esophageal ulcer. It is important to educate patients on proper administration of Pradaxa, to decrease the risk of this rare, but potentially serious adverse event.

    Topics: Aged; Anticoagulants; Dabigatran; Embolism; Endoscopy, Gastrointestinal; Esophageal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Male; Stomach; Ulcer; Warfarin

2015
Combination of low-dose aspirin and thienopyridine exacerbates small bowel injury.
    Scandinavian journal of gastroenterology, 2011, Volume: 46, Issue:3

    Antithrombotics is increasingly being used for cardiovascular prevention. In more recent studies, small bowel injury and enteropathy associated with low-dose aspirin are increasingly being recognized. Aim of this study was to evaluate small bowel injury using video capsule endoscopy (VCE) in obscure gastrointestinal bleeding (OGIB) patients taking low-dose aspirin including other antithrombotics.. This is a retrospective review of chronic users of antithrombotics who underwent VCE for suspected small bowel bleeding. Small bowel mucosal injury was evaluated using VCE findings.. Fifty-four OGIB patients (36 men and 18 women, mean age 72.4 years) underwent VCE from January 2007 to May 2009. Twenty-two patients were taking 100 mg of enteric-coated aspirin (aspirin group), 8 taking thienopyridine, (ticlopidine or clopidogrel, thienopyridine group), 13 taking aspirin combined with thienopyridine (combined group), and 11 taking warfarin (warfarin group). The mucosal injury, especially ulcers were most frequently detected in the combined group (46.2%, p = 0.01) among the four groups. The median number of redness lesions in the combined group was the highest among the four groups and was significantly higher than that in the warfarin group. The lesions of redness or small erosions in the aspirin and the combined groups tended to exist in the proximal part of small bowel.. Combination of low-dose aspirin therapy and thienopyridine may exacerbate small bowel injury, and the preventive strategies should be established.

    Topics: Aged; Aged, 80 and over; Aspirin; Capsule Endoscopy; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agents; Gastrointestinal Hemorrhage; Humans; Intestinal Mucosa; Intestine, Small; Male; Middle Aged; Pyridines; Retrospective Studies; Ticlopidine; Ulcer; Warfarin

2011
Livedoid vasculopathy secondary to high levels of lipoprotein(a).
    The British journal of dermatology, 2011, Volume: 164, Issue:5

    Topics: Anticoagulants; Female; Humans; Lipoprotein(a); Livedo Reticularis; Middle Aged; Ulcer; Warfarin; Young Adult

2011
Risk of low-dose aspirin: emphasis on outliers undermines the credibility of the conclusions.
    Alimentary pharmacology & therapeutics, 2007, Feb-01, Volume: 25, Issue:3

    Topics: Adrenal Cortex Hormones; Aging; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Drug Administration Schedule; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Humans; Randomized Controlled Trials as Topic; Risk Factors; Ulcer; Warfarin

2007
Oesophageal ulcer caused by warfarin.
    Postgraduate medical journal, 1989, Volume: 65, Issue:762

    Oesophageal injury is a well recognized complication of certain oral medications but warfarin has not been implicated previously. We present a case of an oesophageal ulcer occurring in a patient with mitral regurgitation taking warfarin, and demonstrate a delayed oesophageal tablet transit time.

    Topics: Drug Administration Schedule; Esophageal Diseases; Female; Humans; Middle Aged; Ulcer; Warfarin

1989